How do treatments become recognised, and recommended in low-grade serous ovarian cancer? Dr Brian Slomovitz from Mount Sinai Medical Center in Miami discusses the process for identifying and validating treatments in low-grade serous ovarian cancer, including the role of drug repurposing and how treatments become approved by drug regulation bodies like the FDA.
This presentation was given as part of our American research partner STAAR‘s LGSOC Patient Conference in Houston, Texas in February 2025.
Visit STAAR Low-Grade Serous Ovarian Cancer Foundation’s video library to watch more presentations from their LGSOC conference.
Special thanks to conference video sponsor Not These Ovaries.
